Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
News|Videos|December 19, 2025
Impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X)
Author(s)Brian M. Shuch, MD
Brian M. Shuch, MD, discusses the impact of 89Zr-girentuximab PET/CT versus conventional imaging on clinical decision making in patients with indeterminate renal masses (ZIRCON-X).
Advertisement
The ZIRCON-X study evaluated whether adding ⁸⁹Zr-girentuximab PET/CT to standard imaging could influence clinical decision-making in patients with indeterminate renal masses suspicious for clear cell renal cell carcinoma. Results showed that nearly half of patients would have had a change in management, often a major one, suggesting this CAIX-targeted PET imaging may significantly improve diagnostic clarity and guide more appropriate treatment decisions.
Advertisement
Related to this article
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
Roswell Park Comprehensive Cancer Center received a grant to advance CAR T-cell therapy research in pediatric AML.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
Safusidenib produced a 51.9% confirmed ORR and a 79.1% 36-month PFS rate in chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
The OncFive: Top Oncology Articles for the Week of 7/19
3
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
4
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
5